Nuvigil launch brings up more questions about whether new isomers or metabolites of existing drugs are better than the original

The recent Nuvigil launch brings up more questions about whether new isomers or metabolites of existing drugs are better than the original.

These "follow-on" drugs are the latest trend for drug companies looking to replace drugs with expiring patents.

But these new versions usually don't offer much improvement.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote